PRMT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistently, Prmt1 KO prolonged survival (median survival: WT vs Prmt1 KO was 20 days vs not reached after monitoring for 80 days; Figure 2D), and ameliorated splenomegaly and spleen weight of CML mice (Figure 2E,F).